Loading
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Latest quote
$9.91
+$0.16 · +1.64%
After-hours
$9.90
−$0.01 · -0.10%
Oct 8, 7:02 PM ET
Regular session · ET · Market data may be delayed.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Day range
Current $9.91
52-week range
Current $9.91
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
44
Fair Value
Sentiment
68
Bullish
Risk
49
Elevated Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Day range
Current $9.91
52-week range
Current $9.91
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 113.29M USD | 14.75M USD | 622K USD | 240K USD | 934K USD |
| Cost of goods sold | 753K USD | — | — | — | — |
| Gross profit | 112.54M USD | 14.75M USD | 622K USD | 240K USD | 934K USD |
| Research and development | 207.88M USD | 190.14M USD | 232.37M USD | 248.15M USD | 195.96M USD |
| Selling, general, and administrative | 147.18M USD | 168.78M USD | 129.62M USD | 102.71M USD | 135.26M USD |
| Operating expenses | 368.56M USD | 358.93M USD | 362.87M USD | 351.54M USD | 331.21M USD |
| Interest income | 6.7M USD | 2.4M USD | 863K USD | 2.71M USD | 836K USD |
| Interest expense | 112.53M USD | 131.66M USD | 86.72M USD | 47.15M USD | 14.85M USD |
| Depreciation and amortization | 15.53M USD | 17.55M USD | 18.51M USD | 18.26M USD | 14.24M USD |
| Operating income | −256.03M USD | −344.18M USD | −362.25M USD | −351.3M USD | −330.28M USD |
| Net income | −351.4M USD | −413.56M USD | −583.2M USD | −416.57M USD | −346.79M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
21.09% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI117.26M1.16%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM98.8M0.13%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Total Stock Market ETFVTI92.41M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB67.01M0.04%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK38.38M0.08%44.7B USD0.05%$340.59-0.48%
iShares Russell 2000 Growth ETFIWO35.25M0.25%14.25B USD0.24%$353.47-0.53%
Vanguard Extended Market ETFVXF30.02M0.03%95.4B USD0.05%$233.13-0.15%
iShares Biotechnology ETFIBB29M0.28%10.4B USD0.44%$200.48-1.41%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
